Advertisement
News
Advertisement

FDA approves treatment for HIV-linked abdominal fat

Thu, 11/11/2010 - 9:35am
Mass High Tech: The Journal of New England Technology

The U.S. Food and Drug Administration has approved a treatment, developed by Canadian firm Theratechnologies and marketed exclusively in the U.S. by Rockland-based EMD Serono, for excess abdominal fat in HIV-infected patients with lipodystrophy.

The treatment, called EGRIFTA (tesamorelin for injection), is the only therapy for abdominal lipohypertrophy, according to a news release from EMD Serono. Tesamorelin is an analogue of the human growth hormone releasing factor. EGRIFTA’s long-term cardiovascular safety has not been studied, but two Phase 3 clinical trials have shown patients’ waist circumference and visceral adipose tissue were reduced in those taking EGRIFTA, as opposed to placebo. 

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading